Goldman Sachs upgraded Eli Lilly (LLY) to Buy from Neutral with a price target of $888, down from $892, after assuming coverage of the name. Following the recent selloff, Eli Lilly shares offer a “compelling entry point into the sector’s premier topline grower,” the analyst tells investors in a research note. The firm believes the company “will maintain its pole position” as the leader in the anti-obesity medication market, which Goldman says it set to triple in size from$28B today to $95B by 2030.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly & Co.: Strategic Market Leadership and Growth Potential Justify Buy Rating
- Eli Lilly & Co: Strategic Global Expansion and R&D Commitment Drive Buy Rating
- Eli Lilly & Co: Strong Growth and Potential Coverage Expansion Justify Buy Rating
- Biotech Alert: Searches spiking for these stocks today
- Trump Trade: Trump claims ‘no inflation,’ Medicare won’t cover obesity drugs